

LANDOS BIOPHARMA, INC.
1800 Kraft Drive, Suite 216
Blacksburg, VA 24060

February 1, 2021

VIA EDGAR

United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attn: Jenn Do
Kevin Kuhar
Christopher Edwards
Alan Campbell

**RE: Landos Biopharma, Inc.
Registration Statement on Form S-1
File No. 333-252083**

Acceleration Request

**Requested Date: February 3, 2021
Requested Time: 4:00 P.M. Eastern Time**

Ladies and Gentlemen:

In accordance with Rule 461 under the Securities Act of 1933, as amended, the undersigned registrant (the "**Registrant**") hereby requests that the Securities and Exchange Commission take appropriate action to cause the above-referenced Registration Statement on Form S-1 (the "**Registration Statement**") to become effective on February 3, 2021, at 4:00 p.m., Eastern Time, or as soon thereafter as is practicable.

Once the Registration Statement has been declared effective, please orally confirm that event with Madison Jones, counsel to the Registrant, at (202) 728-7087.

Very truly yours,

Landos Biopharma, Inc.

/s/ Josep Bassaganya-Riera

Josep Bassaganya-Riera
Chairman, President and Chief Executive Officer

cc: Eric Blanchard, Cooley LLP
Madison Jones, Cooley LLP